Comparison 2. Indacaterol vs LABAs.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Trough FEV1 (by dose)	4	2708	Mean Difference (Fixed, 95% CI)	73.76 [57.33, 90.19]
1.1 Indacaterol 150 mcg	2	1625	Mean Difference (Fixed, 95% CI)	62.56 [42.71, 82.40]
1.2 Indcaterol 300 mcg	2	625	Mean Difference (Fixed, 95% CI)	97.17 [60.51, 133.83]
1.3 Indacaterol 600 mcg	1	458	Mean Difference (Fixed, 95% CI)	100.0 [51.21, 148.79]
2 Trough FEV1 (by trial duration)	4	2708	Mean Difference (Fixed, 95% CI)	94.93 [79.58, 110.28]
2.1 Trials < 24 weeks	1	1034	Mean Difference (Fixed, 95% CI)	60.0 [37.00, 83.00]
2.2 Trials ≥ 24 weeks	3	1674	Mean Difference (Fixed, 95% CI)	122.98 [102.37, 143.59]
3 Quality of life (by dose)	2	1523	Mean Difference (Fixed, 95% CI)	‐0.81 [‐2.28, 0.66]
3.1 Indacaterol 150 mcg	1	591	Mean Difference (Fixed, 95% CI)	‐1.2 [‐3.42, 1.02]
3.2 Indacaterol 300 mcg	1	474	Mean Difference (Fixed, 95% CI)	‐0.5 [‐3.27, 2.27]
3.3 Indacaterol 600 mcg	1	458	Mean Difference (Fixed, 95% CI)	‐0.5 [‐3.27, 2.27]
4 Quality of lIfe (by trial duration)	2	1523	Mean Difference (Fixed, 95% CI)	0.42 [‐1.21, 2.05]
4.1 Trials ≥ 24 weeks	2	1523	Mean Difference (Fixed, 95% CI)	0.42 [‐1.21, 2.05]
5 Number of participants with a clinically significant improvement in quality of life (by dose)	2	1520	Odds Ratio (Fixed, 95% CI)	1.07 [0.87, 1.32]
5.1 Indacaterol 150 mcg	1	591	Odds Ratio (Fixed, 95% CI)	1.17 [0.85, 1.61]
5.2 Indacaterol 300 mcg	1	473	Odds Ratio (Fixed, 95% CI)	0.93 [0.63, 1.37]
5.3 Indacaterol 600 mcg	1	456	Odds Ratio (Fixed, 95% CI)	1.09 [0.74, 1.61]
6 Number of participants with a clinically significant improvement in quality of life (by trial duration)	2	1520	Odds Ratio (Fixed, 95% CI)	1.06 [0.86, 1.31]
6.1 Trials ≥ 24 weeks	2	1520	Odds Ratio (Fixed, 95% CI)	1.06 [0.86, 1.31]
7 Dyspnoea (by dose)	3	2404	Mean Difference (Fixed, 95% CI)	0.54 [0.30, 0.79]
7.1 Indcaterol 150 mcg	2	1485	Mean Difference (Fixed, 95% CI)	0.66 [0.37, 0.95]
7.2 Indacaterol 300 mcg	1	468	Mean Difference (Fixed, 95% CI)	0.19 [‐0.46, 0.84]
7.3 Indacaterol 600 mcg	1	451	Mean Difference (Fixed, 95% CI)	0.3 [‐0.35, 0.95]
8 Number of participants experiencing a clinically significant improvement in dyspnoea	3	2536	Odds Ratio (Fixed, 95% CI)	1.11 [0.94, 1.32]
8.1 Indacaterol 150 mcg	2	1620	Odds Ratio (Fixed, 95% CI)	1.21 [0.98, 1.50]
8.2 Indacaterol 300 mcg	1	467	Odds Ratio (Fixed, 95% CI)	0.87 [0.59, 1.29]
8.3 Indacaterol 600 mcg	1	449	Odds Ratio (Fixed, 95% CI)	1.06 [0.72, 1.58]
9 Peak FEV1 [mL]	2	491	Mean Difference (IV, Fixed, 95% CI)	4.68 [‐93.79, 103.16]
9.1 indacaterol 150 mcg	1	220	Mean Difference (IV, Fixed, 95% CI)	40.0 [‐113.72, 193.72]
9.2 indacaterol 300 mcg	1	139	Mean Difference (IV, Fixed, 95% CI)	‐30.0 [‐212.29, 152.29]
9.3 indacaterol 600 mcg	1	132	Mean Difference (IV, Fixed, 95% CI)	‐10.0 [‐190.45, 170.45]
10 Serious adverse events	4	3266	Odds Ratio (M‐H, Fixed, 95% CI)	1.02 [0.79, 1.32]
10.1 indacaterol 150 mcg	2	1784	Odds Ratio (M‐H, Fixed, 95% CI)	1.44 [0.92, 2.25]
10.2 indacaterol 300 mcg	2	840	Odds Ratio (M‐H, Fixed, 95% CI)	1.00 [0.66, 1.52]
10.3 indacaterol 600 mcg	1	642	Odds Ratio (M‐H, Fixed, 95% CI)	0.71 [0.45, 1.13]
11 Mortality	4	3266	Odds Ratio (M‐H, Fixed, 95% CI)	1.00 [0.31, 3.28]
11.1 indacaterol 150 mcg	2	1784	Odds Ratio (M‐H, Fixed, 95% CI)	2.35 [0.35, 15.98]
11.2 indacaterol 300 mcg	2	840	Odds Ratio (M‐H, Fixed, 95% CI)	0.82 [0.11, 6.27]
11.3 indacaterol 600 mcg	1	642	Odds Ratio (M‐H, Fixed, 95% CI)	0.17 [0.01, 4.18]
12 Number of participants experiencing at least 1 protocol‐defined exacerbation	2	1869	Odds Ratio (M‐H, Fixed, 95% CI)	1.04 [0.84, 1.29]
12.1 indacaterol 150 mcg	1	668	Odds Ratio (M‐H, Fixed, 95% CI)	1.21 [0.80, 1.82]
12.2 indacaterol 300 mcg	1	605	Odds Ratio (M‐H, Fixed, 95% CI)	1.06 [0.74, 1.53]
12.3 indacaterol 600 mcg	1	596	Odds Ratio (M‐H, Fixed, 95% CI)	0.90 [0.62, 1.30]